Unusual Presentation Of Self-Limiting Chorioretinopathy Possibly Associated With COVID-19

D. Popov; V. Dudulova; G. Popova; M. Mineva

doi:10.14748/bro.v65i2.7823

Unusual Presentation Of Self-Limiting Chorioretinopathy Possibly Associated With COVID-19

D. Popov, V. Dudulova, G. Popova, M. Mineva

Abstract

The paper reports on an unusual presentation of self-limiting chorioretinopathy possibly associated with COVID-19 in a 47-year-old woman previously tested positive for SARS-COV-2 by PCR, who presented with decreased VA in her right eye on day 15 after testing. The only symptom she had was anosmia and аgeusia. No therapy was taken during the 14-days quarantine period. The anterior segment was unremarkable on slit lamp examination in both eyes. Fundus examination of the left eye showed no significant findings. On the other hand, the examination of the right eye revealed yellowish creamy deep chorioretinal lesion in central retina. Two weeks later the patient came back for follow-up and it was found that the lesion was decreased in size, with VA improvement. Ocular signs in COVID-19 cases are rarely reported, and most of the ophthalmological changes have been associated usually with viral conjunctivitis. Researchers report also finding such as cotton wool spots, microhemorrhages and some OCT-changes. This case illustrates the possible association between COVID-19 and retinopathy despite the almost asymptomatic presentation.

Keywords

COVID-19, chorioretinopathy, unusual presentation, yellowish creamy deep lesion

Full Text

References

COVID-19 Clinical management: living guidance 25 January 2021 – WHO/2019-nCoV/clinical/2021.1

Becker RC. COVID-19-associated vasculitis and vasculopathy. J Thromb Thrombolysis. 2020; 50(3):499-511. doi:10.1007/s11239-020-02230-4.

Landecho MF, Yuste JR, Gándara E, et al. COVID-19 retinal microangiopathy as an in vivo biomarker of systemic vascular disease? J Intern Med. 2021 Jan; 289(1):116-120.

Nasiri N, Sharifi H, Bazrafshan A, et al. Ocular Manifestations of COVID-19: A Systematic Review and Meta-analysis. J Ophthalmic Vis Res. 2021 Jan-Mar; 16(1): 103-112.

Wu P, Duan F, Luo C, et al. Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. 2020. doi:10.1001/jamaophthal- mol.2020.1291

Seah IYJ, Anderson DE, Kang AEZ, et al. Assessing Viral Shedding and Infectivity of Tears in Corona- virus Disease 2019 (COVID-19) Patients. Ophthalmology. 2020. doi:10.1016/j.ophtha.2020.03.026

Mungmungpuntipantip R, Wiwanitkit V. Ocular manifestation, eye protection, and COVID-19. Graefes Arch Clin Exp Ophthalmol. 2020; 258(6):1339. doi:10.1007/s00417-020-04662-3.

Sawant OB, Singh S, Wright RE, et al. Prevalence of SARS-CoV-2 in human post-mortem ocular tis- sues. Ocul Surf. 2021 Jan; 19: 322-329.

Seah I, Agrawal R. Can the Coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. Ocul Immunol Inflamm. 2020; 28(3):391-395.doi:10.1080/09273948.2020.1738501.

Li Y, Zhou W, Yang L, You R. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. Pharmacol Res. 2020; 157:104833. doi:10.1016/j.phrs.2020.104833.

Holappa M, Vapaatalo H, Vaajanen A. Many Faces of Renin-angiotensin System – Focus on Eye. Open Ophthalmol J. 2017; 11:122-142. doi:10.2174/18 74364101711010122.

Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; 191:145-7. doi: 10.1016/j. thromres.2020.04.013.

DOI: http://dx.doi.org/10.14748/bro.v65i2.7823